R&D Systems Inc. Tocris Bioscience Boston Biochem

HU 211

Cat. No. 2861

HU 211 C25H38O3 [112924-45-5]

Price and Availability

For HU 211 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: Dexanabinol

Chemical Name: (6aS,10aS)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol

Biological Activity

NMDA antagonist (IC50 = 11 μM for inhibition of [3H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50 = 3.8 μM) and enhances dopamine D1 receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.

Technical Data

M.Wt:
386.57
Formula:
C25H38O3
Solubility:
Soluble to 100 mM in DMSO and to 100 mM in ethanol
Purity:
>97 %
Storage:
Store at -20°C
CAS No:
112924-45-5

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Eshhar et al (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 237. PMID: 8298080.

Gallily et al (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J.Pharmacol.Exp.Ther. 283 918. PMID: 9353414.

Striem et al (1997) Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur.J.Pharmacol. 338 205. PMID: 9424014.

Juttler et al (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB). Neuropharmacology 47 580. PMID: 15380375.

If you know of a relevant citation for this product please let us know.

Keywords: HU 211, supplier, NF-κB, NF-kappaB, NF-kB, inhibitors, decreases, TNF-α, TNF-alpha, IL-6, NO, production, NMDA, antagonists, receptors, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, HU211

Quick Order

Find multiple products by catalog number

divider line

Pain Research Product Guide

Pain Research Guide

Highlights over 280 products for Pain research. Request copy or view PDF today.

divider line

Neurodegeneration Research Product Guide

Neurodegeneration Research Guide

Highlights over 250 products for neurodegeneration research. Request a copy or view PDF today.

divider line

Learning and Memory

Written by Clea Warburton and Zafar Bashir

Learning and Memory Poster

An overview of the cellular mechanisms underlying recognition memory and its links to long-term depression. Request a copy or view PDF today.

divider line

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

Neuroprotection Poster

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

divider line

Peripheral Sensitization

Written by Grant D. Nicol and Michael R. Vasko

Pain Poster

A summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. Request a copy or view PDF today.

divider line

Neurobiology of Parkinson's Disease

Written by A. Schapira

Parkinson's Poster

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.

divider line

Antidepressants - Current and Future Targets

Written by P. Skolnich et al

Antidepressants poster

'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

The Neurobiology of Alzheimer's Disease

Written by Alan Palmer

Alzheimer's Poster

'The Neurobiology of Alzheimer's Disease' summarizes structural and functional changes observed in the progression of AD.

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

Bio-Techne Events

2014 ASCB/IFCB meeting

ASCB/IFCB 2014

December 6 - 10, 2014

Philadelphia, USA

Booth Number: 515